Searched for
GEODON
Brokerages lower Wockhardt's target price after USFDA import alert on Chikalthana plantThe USFDA import alert on Wockhardt's second plant will have a negative impact on the pharma major, say brokerages.- Dr Reddy’s Q2 PAT seen at Rs 370 croreAccording to analysts, the US markets will be key growth driver and may show 22 – 25 per cent growth in the second quarter.
- Preview: Lupin PAT seen up 4% YoY; higher input cost to dent marginsAccording to ET NOW, domestic formulations business is likely to grow by 20-23 per cent while the exports may see growth of 35 per cent. Hi...
- Wockhardt gets tentative USFDA nod for anti-psychotic drugPharmaceutical firm Wockhardt today said it has received tentative approval from US health regulator for its generic version of anti-psycho...
- Brokerages maintain 'hold' on Dr Reddy's post resultsShares of Dr Reddy’s Laboratories (DRL) were down on profit booking after the company disappointed the street with its quarterly results ye...
- Unfair practices: Pharma cos GlaxoSmithkline, Pfizer, Johnson & Johnson and others fined $13 bn in 4 yearsGlaxoSmithkline, Pfizer, Johnson & Johnson, AstraZeneca, Merck, Abbot, Eli Lilly and Allergen have paid about $13 billion in fines to settl...
- Why Dr Reddy's labs is going to report good resultsThe Hyderabad-based company with FY12 net sales Rs 9674 crore is expected to report good results to the cheer of its investors.
- Indian drug outlook favourable: ICRA & Moody'sAccording to the report, domestic formulation market size stood at Rs 58,300 crore, ranked third in terms of volume and tenth in terms of v...
- Dr Reddy's Q4 net profit seen at Rs 448cr, up 34% YoYDr Reddy's Laboratories is expected to report a 34% YoY increase in net profit to Rs 448 crore for the fourth quarter, according to an ET N...
- Lupin Q4 net profit seen up 16% at Rs 263 croreLupin is expected to report a 16 percent YoY increase in its fourth quarter net profit at Rs 263 crore from Rs 227 crore in the year-ago pe...
- Brokers' Call: ONGC, DRL, Cipla and Coal IndiaWe have compiled stock views and recommendations from various agencies on ONGC, Dr Reddy's, Cipla and Coal India.
- Dr Reddy's Lab can Touch 1,950: HSBCHSBC has reiterated its 'Overweight' rating on Dr Reddy's Lab and set a target price of 1,950.
- Dr Reddy's launches Ziprasidone Hydrochloride capsules in USDr Reddy's Laboratories announced today that it has launched Ziprasidone Hydrochloride Capsules, a bioequivalent generic version of Geodon,...
- Dr Reddy's launches generic version of Pfizer's Geodon capsules in US marketDr Reddy's Lab said it has launched a generic version of Pfizer's Geodon capsules in the US market, used in treating mental disorders.
- Hedged all forex exposure for short term: S Ramesh, CFO, LupinIn an interview with ET Now, S Ramesh, CFO, Lupin, talks about pharma and company's strategies.
- Looking at acquisitions in Latin Ameican market: S Ramesh, Lupin Ltd.S Ramesh, President Finance and Planning, Lupin Ltd. in an interview with ET Now talks about the expected growth from the US market and the...
- Pfizer faces US probe, to pay $2.3 bnPfizer will pay $2.3 bn to settle a US investigation into illegal marketing of medicines, the largest agreement in such a case, and a subsi...
- Children's disorders increases sales of US pharma cosSales for children of antipsychotic medicines have exploded, fuelled by a 40-fold increase over nine years in the number of children diagno...
- Lupin receives USFDA nod for anti-psychotic drugDomestic pharma company Lupin Ltd on Monday said it has received tentative approval from the US Food and Drug Administration (USFDA) for it...
- Pfizer Q3 profit doubles to $3.4bnPfizer on Thursday said third-quarter earnings doubled from the year-ago quarter when it took a big merger-related charge, helped by strong...
Load More
